 HOUSTON, Dec. 10, 2020 GLOBE NEWSWIRE -- Salarius Pharmaceuticals, Inc. Nasdaq: SLRX, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the receipt of a 0.8 million payment as part of an expected 1.7 million in payments under its contract with the Cancer Prevention and Research Institute of Texas CPRIT. The payments are part of an original non-dilutive grant of up to 18.7 million awarded in 2016 to support Salarius operations and development of its lead drug candidate, seclidemstat, for the treatment of Ewing sarcoma and other cancers. Seclidemstat is a reversible LSD1 inhibitor being studied in two clinical trials one trial in relapsedrefractory Ewing sarcoma, a rare and deadly pediatric bone cancer, and a second trial in advanced solid tumors AST. 